Risk of hepatic events in patients treated with vancomycin in clinical studies: A systematic review and meta-analysis

Drug Safety

Volumn 34, Issue 1, 2011, Pages 73-82

  Chen, Yan ^a   Yang, Xiao Yan ^a   Zeckel, Michael ^a   Killian, Chris ^a   Hornbuckle, Kenneth ^a   Regev, Arie ^a   Voss, Simon ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Antibacterials, adverse reactions; Liver function; Liver injury, drug induced; Meta analysis; Vancomycin, adverse reactions

Indexed keywords

AMIKACIN; AZTREONAM; BETA LACTAM; CEFTAROLINE; CEFTAZIDIME; CEPHALOSPORIN; DAPTOMYCIN; LINEZOLID; PENICILLIN G; PENICILLINASE; PLACEBO; TEICOPLANIN; TELAVANCIN; TICARCILLIN; TIGECYCLINE; TIMENTIN; VANCOMYCIN;

AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BACTEREMIA; COMBINATION CHEMOTHERAPY; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; GRAM POSITIVE INFECTION; HUMAN; LIVER DYSFUNCTION; LIVER FUNCTION TEST; LIVER TOXICITY; META ANALYSIS (TOPIC); MONOTHERAPY; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SEPSIS; SIDE EFFECT; SKIN INFECTION; SYSTEMATIC REVIEW; TOXIC HEPATITIS;

ANTI-BACTERIAL AGENTS; DRUG MONITORING; DRUG-INDUCED LIVER INJURY; HUMANS; PUBLICATION BIAS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK; SEVERITY OF ILLNESS INDEX; TRANSAMINASES; VANCOMYCIN;

EID: 78651503037     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11539560-000000000-00000     Document Type: Article

References (41)

1. Griffith RS. Introduction to vancomycin. Rev Infect Dis 1981; 3: S200-4.
2. Anderson RCGR, Higgins Jr HM, Pettinga CD. Sympo-sium: how a drug is born. Cincinnati J Med 1961; 42: 49-60.
3. Moellering RC. Vancomycin: a 50-year reassessment. Clin Infec Dis 2006; 42 Suppl. 1: S3-4.
4. Farber BF, Moellering Jr RC. Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981. Antimicrob Agents Chemother 1983; 23: 138-41.
5. Elting LS, Rubenstein EB, Kurtin D, et al. Mississippi mud in the 1990s: risks and outcomes of vancomycin-associated toxi-city in general oncology practice. Cancer 1998; 83: 2597-607.
6. Chen Y, Guo JJ, Steinbuch M, et al. Comparisons of data mining algorithms for signal detection: an empirical study based on the Adverse Event Reporting System of the Food and Drug Administration. Pharmaceut Med 2008; 22 (6): 359-69.
7. Chen Y, Guo JJ, Healy DP, et al. The risk of hepatotoxicity associated with the use of Ketek: signal detection based upon FDA Spontaneous Reporting System. Ann Pharma-cother 2008; 42 (12): 1791-6.
8. Cadle RM, Mansouri MD, Darouiche RO. Vancomycin-induced elevation of liver enzyme levels. Ann Pharma-cother 2006; 40: 1186-9.
9. Sikuler E, Guetta V, Keynan A, et al. Abnormalities in bil-irubin and liver enzyme levels in adult patients with bac-teremia: a prospective study. Arch Intern Med 1989; 149: 2246-8.
10. Jaded AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12.
11. Sierra F. Evidence-based medicine (EBM) in practice: ap-plying number needed to treat and number needed to harm. Am J Gastroenterol 2005; 100: 1661-3.
12. RevMan 4.2 user guide. Oxford: The Cochrane Collabora-tion, 2004; 82-4.
13. Cochran WG. The combination of estimates from different experiments. Biometrics 1954; 10: 101-29.
14. Egger M, Smith GD, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-34.
15. Shenep JL, Hughes WT, Roberson PK, et al. Vancomycin, ticarcillin, and amikacin compared with ticarcillin-clavulanate and amikacin in the empirical treatment of febrile, neutropenic children with cancer. N Engl J Med 1988; 319 (16): 1053-8.
16. Calandra T, Zinner SH, Glauser MP, et al. Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. European Organization for Research and Treatment of Cancer (EORTC). J Infect Dis 1991; 163 (5): 951-8.
17. Wilson AP, Gruneberg RN, Neu H. A critical review of the dosage of teicoplanin in Europe and the USA. Int J Anti-microb Agents 1994; 4 Suppl. 1: S1-40.
18. Breedt J, Teras J, Gardovskis J, et al. Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase III comparison study with vancomycin-aztreonam. Tigecycline 305 cSSSI Study Group. Antimicrob Agents Chemother 2005; 49(11): 4658-66.
19. Sacchidanand S, Penn RL, Embil JM, et al. Efficacy and safety of tigecycline monotherapy compared with vanco-mycin plus aztreonam in patients with complicated skin and skin structure infections: results from a phase III, randomized, double-blind trial. Int J Infect Dis 2005; 9 (5): 251-61.
20. Stryjewski ME, Graham DR, Wilson SE, et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis 2008; 46: 1683-93.
21. Stryjewski ME, Chu VH, O'Riordan WD, et al. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study. Antimicrob Agents Chemother 2006; 50 (3): 862-7.
22. Stryjewski ME, O'Riordan WD, Lau WK, et al. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria. Clin Infect Dis 2005; 40 (11): 1601-7.
23. Arbeit RD, Maki D, Tally FP, et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004; 38 (12): 1673-81.
24. Lin DF, Zhang YY, Wu JF, et al. Linezolid for the treat-ment of infections caused by Gram-positive pathogens in China. Int J Antimicrob Agents 2008; 32 (3): 241-9.
25. Jantausch BA, Deville J, Adler S, et al. Linezolid for the treatment of children with bacteremia or nosocomial pneumonia causedby resistant gram-positive bacterial pathogens. Pediatr Infect Dis J 2003; 22 (9 Suppl.): S164-71.
26. Deville JG, Adler S, Azimi PH, et al. Linezolid versus van-comycin in the treatment of known or suspected resistant gram-positive infections in neonates. Pediatr Infect Dis J 2003; 22 (9 Suppl.): S158-63. (Pubitemid 37158764)
27. Kaplan SL, Deville JG, Yogev R, et al. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children. Linezolid Pediatric Study Group. Pediatr Infect Dis J 2003; 22 (8): 677-86.
28. Talbot GH, Thye D, Das A, et al. Phase 2 study of ceftaro-line versus standard therapy in treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother 2007; 51 (10): 3612-6.
29. Vazquez L, Encinas MP, Morin LS, et al. Randomized prospective study comparing cost-effectiveness of teico-planin and vancomycin as second-line empiric therapy for infection in neutropenic patients. Haematologica 1999; 84 (3): 231-6.
30. Rubinstein E, Cammarata S, Oliphant T, et al. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Linezolid Nos-ocomial Pneumonia Study Group. Clin Infect Dis 2001; 32 (3): 402-12.
31. Florescu I, Beuran M, Dimov R, et al. Efficacy and safety of tigecycline compared with vancomyin or linezolid for treatments of serious infections with methicillin-resistant staphylococcus aureus or vancomycin-resistant enterococci: a phase 3, multicentre, double-blind, randomized study. J Antimicrob Chemother 2008; 62 Suppl.: i17-28.
32. Lv YH, Zhou QY, Li XH, et al. Clinical evaluation of van-comycin in treatment of neonatal infection pneumonia in NICU. Chin J Birth Health Hered 2004; 12: 95-6.
33. Neville LO, Brumfitt W, Hamilton-Miller JMT, et al. Teicoplanin vs. vancomycin for the treatment of serious infections: a randomized trial. Int J Antimicrob Agents 1995; 5: 187-93.
34. Kohno S, Yamaguchi K, Aikawa N, et al. Linezolid versus van-comycin for the treatment of infections caused by methicillin-resistant Staphylococcus aureus in Japan. J Antimicrob Chemother 2007; 60: 1361-9.
35. FDA. Guidance for industry. Drug-induced liver injury: premarketing clinical evaluation [online]. Available from URL: http://www.fda.gov/downloads/ Drugs/GuidanceCom plianceRegulatoryInformation/Guidances/UCM174090.pdf [Accessed 2009 Aug 7].
36. Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin Liver Dis 2002; 22: 145-55.
37. Holt MP, Ju C. Mechanisms of drug-induced liver injury. AAPS J 2006; 8: E48-54.
38. Blazka ME, Wilmer JL, Holladay SD, et al. Role of pro-inflammatory cytokines in acetaminophen hepatotoxicity. Toxicol Appl Pharmacol 1995; 133: 43-52.
39. Naisbitt DJ, Farrell J, Wong G, et al. Characterization of drug specific T cells in lamotrigine hypersensitivity. J Allergy Clin Immunol 2003; 111: 1393-403.
40. Hamilton JR, Sass-Kortsak A. Jaundice associated with se-vere bacterial infection in young infacts. J Pediatr 1963; 63: 121-32.
41. Rosner B. The binomial distribution. In: Rosner B. Funda-mentals of biostatistics. Belmont (CA): Duxbury Press, 1995: 82-5